Clinical trials: Prostate Brachytherapy
Biochemical Relapse Free Survival, Complications Rates (Erectile Dysfunction, GI, GU Complications)
HDR Brachytherapy vs SABR in Early-intermediate Prostate Cancer
This is single center prospective phase 2 randomized trial aiming to compare biochemical and clinical relapse free survival and toxicity profiles of stereotactic body radiotherapy (SBRT) versus high dose rate brachytherapy (HDRB)…
- Trial name
- NCT04870567
- Testing
- Stereotactic ablative radiotherapy, High dose rate brachytherapy
- Where
- Russia
- Volunteers
- 350 people
- Sponsor
- N.N. Petrov National Medical Research Center of Oncology
Prostate Cancer
High Versus Low Dose Supplemental External Radiation With Pd-103 for Prostate Cancer
Objective: The objective of this study is test the hypothesis that delivering a higher percentage of the radiation dose as external radiation versus implant will lead to higher tumor control rates.
- Trial name
- NCT00494546
- Testing
- Pd-103 with 20 vs 44 Gy supplemental beam XRT
- Where
- United States
- Volunteers
- 568 people
- Sponsor
- VA Puget Sound Health Care System
Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8
Comparison of High-Dose Rate Brachytherapy and Stereotactic Ablative Radiotherapy as Monotherapy for the Treatment of Localized Prostate Cancer
This phase II trial compares high-dose rate brachytherapy and stereotactic ablative radiotherapy as monotherapy in treating patients with prostate cancer that has not spread to other parts of the body (localized).
- Conditions
- Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8
- Trial name
- NCT04253483
- Testing
- High-Dose Rate Brachytherapy, Quality-of-Life Assessment, Questionnaire Administration
- Where
- 3 sites in United States
- Volunteers
- 14 people
- Sponsor
- Rutgers, The State University of New Jersey
Prostate Cancer, PD-L1
Immune Profiling After HDR in Local Relapsed Prostate Cancer
Immunotherapy is currently revolutionizing the field in oncology. However, prostate cancer until now fails to respond to classical IO, like PD-1 and CTLA-4 inhibitors.
- Trial name
- PRIMUS (NCT04247217)
- Testing
- HDR salvage brachytherapy
- Where
- Netherlands
- Volunteers
- 10 people
- Sponsor
- Maastricht Radiation Oncology
Prostate Cancer
Prostate Interstitial Brachytherapy With I125 Implant With Target Dose Supplementation in the Tumor Volume Guided by TRINITY® PERINE 3D System
The objective of the FOCUS-Boost project is to implant for the first time with a 3D ultrasound image fusion registration system (3D echo) implant of iodine 125 with precision in a target volume determined by positive biopsies.
- Trial name
- FOCUS-BOOST (NCT05322356)
- Testing
- Interstitial Brachytherapy of the Prostate With Iodine 125 Implant With Target Dose Supplementation in the Tumor Volume Guided by the TRINITY® PERINE 3D
- Where
- France
- Volunteers
- 15 people
- Sponsor
- University Hospital, Grenoble
Prostate Adenocarcinoma, Localized Prostate Carcinoma
Two-fraction HDR Monotherapy for Localized Prostate Cancer
This is a single center single arm prospective pilot study investigating the safety of high dose rate (HDR) brachytherapy as monotherapy delivered in 2 fractions 3 hours apart.
- Trial name
- NCT05665738
- Testing
- High Dose Rate Monotherapy
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of California, San Francisco
Prostate Cancer
Needle Localization During Prostate Brachytherapy Using Power Doppler Ultrasound
This study involves patients who are scheduled for standard care brachytherapy of focal tumours within the prostate, which is normally performed under standard 2-dimensional (2D) ultrasound guidance.
- Trial name
- NCT03861507
- Testing
- Prostate Brachytherapy
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Western University, Canada
Prostate Cancer
Selenomethionine and Finasteride Before Surgery or Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer
RATIONALE: Selenomethionine may slow the growth of prostate cancer. Testosterone can cause the growth of prostate cancer cells. Finasteride may fight prostate cancer by lowering the amount of testosterone the body makes.
- Trial name
- NCT00736645
- Testing
- selenomethionine, finasteride
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Roswell Park Cancer Institute
Prostate Cancer
Interstitial Brachytherapy With or Without External-Beam Radiation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays and other sources to damage tumor cells. Interstitial brachytherapy uses radioactive material placed directly into or near a tumor to kill tumor cells.
- Trial name
- NCT00063882
- Testing
- Brachytherapy (100/110), Brachytherapy (125/145), External Beam Radiation Therapy
- Where
- 170 sites in United States, Canada
- Volunteers
- 588 people
- Sponsor
- Radiation Therapy Oncology Group
Prostate Cancer
Single Fraction Early Prostate Irradiation (SiFEPI)
Recently, HDR brachytherapy delivering only a 19 Gy fraction was proposed as exclusive treatment for low and intermediate risk prostate cancers.
- Trial name
- SiFEPI (NCT02104362)
- Testing
- exclusive single-fraction irradiation
- Where
- France
- Volunteers
- 35 people
- Sponsor
- Centre Antoine Lacassagne
Prostate Cancer
Prostate Volume Changes Following Prostate Brachytherapy With Iodine-125 Seeds
The size of the prostate changes due to insertion of the radioactive seeds. We will measure the prostate size, before and after the procedure.
- Trial name
- NCT00348465
- Testing
- Brachytherapy with Iodine-125 seeds
- Volunteers
- 29 people
- Sponsor
- New York Presbyterian Brooklyn Methodist Hospital
Oligoprogressive Prostate Cancer, Metastatic Prostate Cancer
PSMA PET-Staged Comprehensive Progression-Directed Radiotherapy for Limited Progression in Prostate Cancer
PSMA-OLIGO-PRO is a multicenter, ambispective, observational real-world evidence registry of adults with metastatic hormone-sensitive or metastatic castration-resistant prostate cancer who develop a limited number of progressing…
- Trial name
- PSMA-OLIGO-PRO (NCT07691697)
- Testing
- Comprehensive Progression-Directed Radiotherapy
- Where
- Poland
- Volunteers
- 1,000 people
- Sponsor
- Affidea Nu-med Center of Oncological DIagnostics and Therapy
Prostate Cancer Recurrent, Prostate Cancer
Salvage MR-guided High-Dose-Rate Brachytherapy for Prostate Bed Recurrence After Radiotherapy in the PSMA PET Scan Era
This is an interventional, single-centre, single-arm, non-randomized, prospective, feasibility trial investigating salvage MR-guided High-Dose-Rate brachytherapy for prostate bed recurrence after postoperative radiotherapy.
- Trial name
- SHAPE-PSMA (NCT06508567)
- Testing
- High Dose Rate Brachytherapy
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- University Health Network, Toronto
Prostate Cancer
Ability of a New Design of Iodine 125 Seed to Maintain Intended Position When Implanted in the Prostate
This study compares the ability of a new design of brachytherapy seed for prostate seed implants for treatment of prostate cancer to maintain their intended position in the prostate after being deposited.
- Trial name
- FAST (NCT01174017)
- Testing
- Iodine 125 standard loose brachytherapy seeds, AnchorSeed Iodine 125 brachytherapy prostate implant
- Where
- Canada
- Volunteers
- 41 people
- Sponsor
- British Columbia Cancer Agency
Neoplasms, Prostate
Quality of Life After Permanent Interstitial Iodine Seed Prostate Brachytherapy
Retrospective study to analyze Quality of life in men after iodine seed brachytherapy for localized prostate cancer
- Trial name
- NCT02652000
- Testing
- No intervention in this retrospective study
- Where
- Switzerland
- Volunteers
- 50 people
- Sponsor
- Kantonsspital Graubünden
Prostate Adenocarcinoma
Neoadjuvant Interstitial Brachytherapy Using Diffusing Alpha Emitters Radiation Therapy in Men With Prostate Cancer
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device as a neo-adjuvant therapy in men with prostate cancer
- Trial name
- NCT04543903
- Testing
- Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
- Where
- 3 sites in Israel
- Volunteers
- 1 people
- Sponsor
- Alpha Tau Medical LTD.
Prostate Cancer, HDR
A Study of Focal Salvage High-Dose-Rate Brachytherapy for Prostate Gland Only Recurrence
The purpose of this study is to learn more about what effects the use of high-dose-rate (HDR) brachytherapy on prostate cancer recurrence, seen by AXUMIN PET scan, has on prostate cancer.
- Trial name
- NCT04645810
- Testing
- High-Dose-Rate Brachytherapy
- Where
- United States
- Sponsor
- University of Rochester
Prostate Cancer, Radiotherapy Side Effect
Prostate Reirradiation Toxicity Outcomes Feasibility Study
The RO-PIP trial aims to determine the feasibility of recruitment to a trial randomising patients to salvage ultra-hypofractionated external beam radiotherapy or high dose rate brachytherapy and provide prospective data on…
- Trial name
- RO-PIP (NCT05614700)
- Testing
- Brachytherapy, Sterotactic Body Radiotherapy
- Volunteers
- 60 people
- Sponsor
- University of Leeds
Prostate Cancer
Study of Tamsulosin and/or Dutasteride to Relieve Urinary Symptoms After Brachytherapy for Localized Prostate Cancer
The purpose of this study is to determine whether a drug named tamsulosin (Flomax), or another drug named dutasteride (Avodart), or a combination of these two drugs is effective in improving urinary symptoms and decreasing the…
- Trial name
- NCT00244309
- Testing
- tamsulosin and/or dutasteride
- Where
- United States
- Volunteers
- 348 people
- Sponsor
- Case Comprehensive Cancer Center
Prostate Adenocarcinoma, Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8
Focal Radiation Therapy (HDR-Brachytherapy) for the Treatment of Prostate Cancer
This clinical trial tests the effect of focal radiation therapy, high dose rate-brachytherapy (HDR-BT), in treating patients with prostate cancer.
- Conditions
- Prostate Adenocarcinoma, Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage II Prostate Cancer AJCC v8
- Trial name
- NCT07468903
- Testing
- Biopsy Procedure, Biospecimen Collection, High-Dose Rate Brachytherapy
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Jonsson Comprehensive Cancer Center